Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Overall response rate (ORR)
研究概览
简要总结
This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.
详细描述
This is a Phase II, open-label, Single-center platform study，Based on FUSCC four TNBC subtypes and the results of the previous FUTURE trial, the investigators designed this platform trial, which for combined the TNBC subtyping and genomic sequencing-guided precision targeted therapy for refractory metastatic TNBC patients. In this trial, refractory mTNBC patients eligible for inclusion can be divided into various precision treatment group according to molecular typing and subtyping to evaluate the efficacy and safety of multiple precision targeted treatment. The research therapy arm can be updated with the update of basic translational research in our center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female aged ≥18 years;
- •TNBC invasive breast cancer confirmed by histology (specific definition: ER <1% positive tumor cells by immunohistochemistry are defined as ER negative, PR <1% positive tumor cells are defined as PR negative, HER2 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negative); Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent metastatic breast cancer;
- •Progression after at least one prior therapeutic regimens for advanced/metastatic TNBC
- •At least one measurable lesion according to RECIST 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has not received radiotherapy);
- •The functions of the main organs are basically normal and meet the following conditions:
- •i. Blood routine examination criteria shall meet: HB ≥90 g/L (no blood transfusion within 14 days); The ANC acuity 1.5 x 10^9 /L; PLT acuity 75 x 10^9 /L;
- •ii. Biochemical tests should meet the following criteria: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN, endogenous creatinine clearance > 50 ml/min (Cockcroft-Gault formula);
- •They have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study, and have recovered from the acute toxicity of previous treatment (if surgery was performed, the wound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity;
- •ECOG score ≤1, and life expectancy ≥3 months;
- •Fertile female subjects were required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last use of the study drug;
- •Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up.
排除标准
- •Radiotherapy (except for palliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment, except bisphosphonate (which can be used for bone metastasis);
- •Uncontrolled central nervous system metastases (indicating symptomatic or symptomatic treatment with glucocorticoids or mannitol);
- •A history of clinically important or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6 months;
- •Persistent grade 1 or higher adverse reactions caused by previous treatments. The exception to this is hair loss or something the researchers don't think should be ruled out. Such cases should be clearly documented in the investigator's notes;
- •Underwent major surgery (except minor outpatient procedures, such as placement of vascular access) within 3 weeks of the first course of trial treatment;
- •Pregnant or lactating patients;
- •Malignancy (except basal cell carcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5 years.
研究组 & 干预措施
IM/HER2-low
If patients were triple-negative breast cancer with IM subtype and HER2-low-positive
干预措施: A2: SHR-A1811 with Camrelizumab with famitinib (Drug)
IM/HER2-0
If patients were triple-negative breast cancer with IM subtype and HER2-zero
干预措施: B1: TROP2 ADC (Drug)
IM/HER2-0
If patients were triple-negative breast cancer with IM subtype and HER2-zero
干预措施: B2: TROP2 ADC with Camrelizumab (Drug)
BLIS / HER2-low
If patients were triple-negative breast cancer with BLIS subtype and HER2-low-positive
干预措施: C1: SHR-A1811 (Drug)
IM/HER2-low
If patients were triple-negative breast cancer with IM subtype and HER2-low-positive
干预措施: A1: SHR-A1811 (Drug)
BLIS / HER2-low
If patients were triple-negative breast cancer with BLIS subtype and HER2-low-positive
干预措施: C2: SHR-A1811 with BP102 (Drug)
BLIS /HER2-0
If patients were triple-negative breast cancer with BLIS subtype and HER2-zero
干预措施: D1: TROP2 ADC (Drug)
BLIS /HER2-0
If patients were triple-negative breast cancer with BLIS subtype and HER2-zero
干预措施: D2: TROP2 ADC with BP102 (Drug)
LAR / HER2-low
If patients were triple-negative breast cancer with LAR subtype and HER2-low-positive
干预措施: E1: SHR-A1811 (Drug)
LAR / HER2-low
If patients were triple-negative breast cancer with LAR subtype and HER2-low-positive
干预措施: E2: SHR-A1811 with everolimus (Drug)
LAR /HER2-0
If patients were triple-negative breast cancer with LAR subtype and HER2-zero
干预措施: F1: TROP2 ADC (Drug)
MES/ HER2-low
If patients were triple-negative breast cancer with MES subtype and HER2-low-positive
干预措施: G1: SHR-A1811 (Drug)
MES /HER2-0
If patients were triple-negative breast cancer with MES subtype and HER2-zero
干预措施: H1: TROP2 ADC (Drug)
All-Comer/TQB2102 plus TQB2868
干预措施: TQB2102 with TQB2868 (Drug)
结局指标
主要结局
Overall response rate (ORR)
时间窗: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 3 years)
The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1)
次要结局
- Overall Survival (OS)(Randomization to death from any cause, through the end of study (approximately 3 years))
- Progression Free Survival (PFS)(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 3 years))
- CTCAE scale (V5.0)(Up to One Year during follow-up)
- Duration of Response (DoR)(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study(approximately 3 years))
- Disease Control Rate (DCR)(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study(approximately 3 years))